The White House’s new advanced manufacturing strategy includes the need to “assure access to medical products” and identifies foreign dominance in small molecule, generic pharmaceuticals as a national security risk. It’s not a stretch to see that leading to a section 232 national security review of imports, in line with prior reviews of the steel, aluminum and autos sectors. America’s soaring demand for healthcare services drove $128.6 billion of pharmaceutical and precursor imports in the 12 months to Sept. 30, up 16.8% on a year earlier. Asian markets only account for a minor part of t...